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1. Introduction
Type 2 diabetes mellitus is currently estimated to affect mor
than 5% of the adult population in Western societies, and its inc
dence is expected to increase considerably in the future, in partic
ular owing to the dramatic increase in obesity. The global incidenc
of type 2 diabetes is projected to afﬂict more than 300 millio
0968-0896/$ - see front matter  2012 Elsevier Ltd. All rights reserved.
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z Dr. Nikos G. Oikonomakos sadly passed away on the 31st of August 2008 whi
this manuscript was in preparation. This paper is dedicated to his memory.
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N0-b-D-glucopyranosyl ureas (substituents: Me, Ph, Cl, OH, OMe, NO2, NH
nthesised by ZnCl2 catalysed acylation of O-peracetylated b-D-glucopyranos
of O-peracetylated or O-unprotected glucopyranosylamines and acyl-isocya
e carried out by base or acid catalysed transesteriﬁcations where necessar
t most of these compounds were low micromolar inhibitors of rabbit musc
MGPb). The best inhibitor was the 4-methylbenzoyl compound (Ki = 2.3 lM
f complexes of several of the compounds with RMGPb showed that the ana
ith water molecules, the available space at the b-pocket subsite and induce
e 280s loop compared to RMGPb in complex with the unsubstituted benzo
e key role of the water molecules in ligand binding and structure-based ligan
tudy of selected inhibitors was done to show the ability of the binding afﬁnit
nity of the highest scored docked poses was calculated and correlated wit
i values. Results show that correlation is high with the R-squared (R2) coefﬁ
 2012 Elsevier Ltd. All rights reserve
people worldwide over the next 20 years, and many of those a
fected will be young adults.1
The disease is characterised by hyperglycaemia associated wit
defective insulin production and hepatic and peripheral insuli
resistance. Due to long term complications, it is a major cause o
blindness and renal disease, and is known to signiﬁcantly increas
the risk of cardiovascular disorders.2 Current preventive and ther
apeutic strategies do not achieve adequate control of blood glucos
to prevent chronic morbidity, and are completely ineffective i
40% of all diagnosed cases.3 As a consequence of this, there is
pressure on the research community (both academic and indus
trial) to develop novel healthcare interventions to address this sub
stantial biomedical challenge.4,5
Hepatic glucose output is elevated in type 2 diabetic patient
and current evidence indicates that glycogenolysis (release o
monomeric glucose from the glycogen polymer storage form)
at SciVerse ScienceDirect
dicinal Chemistry
.e lsevier .com/locate /bmc. (2012), doi:10.1016/j.bmc.2011.12.059
an important contributor to the abnormally high production of
glucose by the liver.2,6,7 Glycogen phosphorylase (GP) is the en-
zyme responsible for glycogen breakdown to produce glucose
and related metabolites for energy supply.4,8,9 Due to its key role
in modulation of glycogen metabolism, pharmacological inhibition
of GP has been regarded as an effective therapeutic approach to
treating type 2 diabetes.10,11 Besides the liver tissue GP isoenzymes
are also located in muscle and brain tissue with increased overall
homology and high levels of identity at the catalytic site. Hence,
80 series of studies have been underway, employing both the liver
and the muscle isoenzyme for the design of new antidiabetic
agents. Several classes of compounds have been reported and
extensively surveyed3,10,12,13 for the inhibition of and in complex
with liver and rabbit muscle GP (RMGP).
Distinct binding sites identiﬁed in GP14 include the catalytic site,
the purine inhibitory site (also known as I-site), the allosteric
site, the glycogen storage site, a novel allosteric inhibitor site and
the newly discovered benzimidazole-binding site. The quest for
compounds with higher potency than glucose to inhibit GP activity
90 led to the design of various glucose-based analogues. For this pur-
pose the properties of the catalytic site of GP in the T state (inactive)
conformation were investigated. Speciﬁcally, the crystal structure
of rabbit muscle enzyme revealed that the catalytic site is a long
channel secluded from the bulk solvent. The entrance to this chan-
nel is constrained by a ﬂexible loop (280s) comprising residues
282–286. During allosteric transition the 280s loop changes confor-
mation and acts as a tollgate allowing access of the substrate to the
core of the molecule. Dissection of the catalytic site in the presence
of a collection of b-substituents of D-glucose unveiled two sub-sites
100 of the catalytic channel, previously ﬁlled with water molecules in
the native enzyme. These sites are lined by residues of mixed io-
nic/hydrophobic character.10 Glucose analogues, binding primarily
to the catalytic site, represent the most populated family of GP
inhibitors3,15 comprising among others various derivatives of N-
acyl-b-D-glucopyranosylamines, glucopyranosylidene-spiro-het-
erocycles, N- and C-b-D-glucopyranosyl heterocycles as well as b-
D-glucopyranosyl thiosemicarbazone derivatives.
A selection of N-acyl-b-D-glucopyranosylamine type com-
pounds collected in Chart 1 indicate that increasing hydrophobicity
110 of the acyl moiety makes the inhibition stronger (among 1 to 8, 4 is
the best inhibitor) while the a-D-anomer 9 is ineffective. Phosphor-
ylated b-D-glucopyranosylamine 10 has a very weak effect. Spiro-
cyclization with the proper ‘anomeric’ conﬁguration (11 and 12
vs 13) makes very good inhibitors. Attachment of a further amide
moiety to the ﬁrst one (14, 15) with a hydrophobic part results
in inhibitor 15 whose efﬁciency is comparable to that of the
spiro-hydantoins 11 and 12. Crystallographic analyses of com-
plexes of the above compounds with rabbit muscle glycogen phos-
phorylase b (RMGPb) demonstrated that in most cases a H-bridge
120 exists between the b-D-glucopyranosylamine NH and main-chain
carbonyl of His377 next to the active site (for illustration and
references see Chart 1). This hydrogen bond in 1–4, 6, 7, and 10–
12 makes an important contribution to the binding. Consequently,
a-D-conﬁgurated derivatives 9 and 13 are much weaker inhibitors.
This hydrogen bridge is absent in the complexes of compounds 5,
8, and 14 which again show poor binding. In the case of benzoyl
urea 15 this H-bridge has not been observed in the crystal16 but
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docking methods applied to the catalytic site of GP, while crystallo-
graphic studies of the enzyme-inhibitor complexes allowed to
assess binding peculiarities of the molecules.
1402. Results & discussion
2.1. Synthesis
Although there are many examples of N-substituted-N0-glycosyl
urea derivatives in the literature, at the outset of this work we
could ﬁnd only two structures for N-acyl-N0-glycosyl ureas: per-
O-acetylated N-acetyl- and N-benzoyl-N0-(b-D-glucopyrano-
syl)urea18 (per-O-acetyl protected 14 and 15, respectively). These
derivatives were made by exhaustive acetylation of b-D-glucopyr-
anosyl urea by Ac2O/ZnCl2, and N-benzoylation of 2,3,4,6-tetra-O-
acetyl-b-D-glucopyranosyl urea by BzCl/Py, respectively. For the
150synthesis of the planned new derivatives disconnections A and B
(Scheme 1) were envisaged requiring investigation of reactions be-
tween b-D-glucopyranosylamines and acyl-isocyanates (A) and
acylations of b-D-glucopyranosyl urea (B).
Intermediates for the preparation of the target compounds
(Scheme 2) were obtained from 2,3,4,6-tetra-O-acetyl-b-D-gluco-
pyranosyl azide (17). Per-O-acetylated b-D-glucopyranosylamine
18 was prepared by Raney-nickel reduction of 17. The protected
b-D-glucopyranosyl urea 16 was synthesized by a slight modiﬁca-
tion of a published protocol. N-Acylation of 16 with acid chlorides
160catalysed by ZnCl2 in CHCl3 gave compounds 20–24 in acceptable
yields in most cases. For details of these transformations and refer-
encing, please, consult Supplementary data.
The reaction of glucosylamine 18with in situ prepared acyl-iso-
cyanates19 was probed next. In these reactions the suggested sol-
vent CH3CN had to be dried with extreme care because even
traces of moisture prevented the formation of the acyl-isocyanate.
The yields of these transformations were also good except that for
23. It can be concluded that for the preparation of the per-O-acet-
ylated target compounds 19–24 N-acylation of urea 16 appears
170superior as compared to the other route taking into account the
number and simplicity of the necessary manipulations.
Removal of the protecting groups was performed by the
Zemplén method to get 15, 27, and 28. These reactions had to be
closely controlled by TLC in order to avoid loss of the N-acyl group
aft
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Ple binding is stronger than in any other N-acyl-b-D-glucopyrano-
lamine derivative. This points to the role of interactions of the
hibitor molecule in the b-channel of the enzyme.
The aim of the present study is to investigate interactions of N-
nzoyl-N0-b-D-glucopyranosyl urea derivatives in the b-channel.
this end 15 was modiﬁed by placing neutral apolar and polar,
well as acidic and basic substituents in position 4 of the phenyl
g. Experimentally determined and computed inhibition con-
ntswere compared to evaluate the predictive power ofmolecularease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (201er longer reaction times (cf. Scheme 2). This could not be
hieved during Zemplén deprotection of 20, 21, and 24, therefore,
e respective 25, 26, and 29 were obtained by mild acid catalyzed
nsesteriﬁcation. These problems associated with the deprotec-
n were circumvented by elaborating a procedure to convert
protected glucopyranosylammonium carbamate20 (35) and
yl-isocyanates to N-acyl-N0-b-D-glucopyranosyl ureas, and for
e preparation of 31–33 these conditions were used. Catalytic
duction of 29 furnished amino derivative 30, while that of 33
ve carboxylic acid 34.
Structure elucidation of the new compounds was straightfor-
rd by NMR methods and needs no detailed comments (see Sup-
ementary data for data). Carbonyl resonances of the acyl urea
oieties appeared between 149–157 ppm (–NHCONH–) and
2–171 ppm (–NHCOAr).
. Enzyme kinetics and X-ray crystallographic results
The inhibitory effect of ten new N-b-D-glucopyranosyl urea ana-
ues 25–34 (Table 1) on the enzyme activity was evaluated by ki-
tic assays performed in the direction of glycogen synthesis at pH
and 30 C. The results showed that all compounds are compet-
ve inhibitors of the enzyme activity with Ki values in the low lM
nge (Table 1). Among the substituents introduced in the para-
sition of the phenyl ring only the –CH3 (compound 25) appeared2), doi:10.1016/j.bmc.2011.12.059
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Chart 1. Selected N-acyl-D-glucopyranosylamine type inhibitors of GP.15,17
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25 January 2012to bring about slightly improved afﬁnity (Ki value of 2.3 lM) com
pared to the lead compound 15.
With the aim to interpret the results obtained from the kinet
experiments and provide rationalizations of the binding afﬁnitie
structural studies of RMGPb in complex with six new compound
25–30 were performed at high resolution (Table 1). All derivative
of 15 bound at the catalytic site, as it was clearly indicated by th
2Fo  Fc and Fo  Fc electron density maps (Fig. 1a–f). Additiona
O H
N
OR
RO
RO
RO H
N
O
Ar
O
O
NH2
OR
C NO
Ar
O
O H
N
OR
NH2
O
Ar
O
X
+ +
A B
A B
Scheme 1. Retrosynthetic disconnections of N-acyl-N0-(b-D-glucopyranosyl) urePlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chemelectron density was observed at the new allosteric site for com
pound 29 (Fig. 1g), suggesting weak binding. All six inhibitors in
duced extended conformational changes mainly in the 280s loo
upon binding, similar, not identical though, to those observed i
the RMGPb:15 complex.16 More detailed analysis of the comple
structures was performed by mapping the key hydrogen bon
and van der Waals interactions formed with residues lining th
catalytic site (Tables S2b and S2c). The interactions formed b
the peripheral hydroxyl groups of the glucopyranose moiety a
the catalytic site are maintained in almost all complexes. There
fore, the analyses focused on the alterations in the network of con
tacts that occur when a new neutral, apolar and polar or slightl
acidic and basic functional group was introduced to the paren
molecule (at position 4 of the phenyl ring).
2.2.1. Compound 15
The crystal structure of RMGPb–15 complex (Bzurea) was prev
ously determined to 1.8 Å resolution16; the structural result
showed that upon binding of 15 at the catalytic site, there is a sig
niﬁcant rearrangement of the 280s loop. In speciﬁc, Asn284
sandwiched between the side chains of residues Phe285 an
Tyr613, resulting in the disruption of the inhibitor site located a
the entrance of the catalytic channel. The dramatic shift observe
in the 280s loop (shifts 1.3 to 3.7 Å of Ca atoms compared t. (2012), doi:10.1016/j.bmc.2011.12.059
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Conditions Yield (%) R  R Reaction time Yield (%) 
c 50 H 19 e 15  H 2 h 90 
c 34 CH3 20 f 25  CH3 12 d 54 
c 43 C6H5 21 f 26  C6H5 6 d 86 
d 67 Cl 22 e 27  Cl 1 h 86 
c 
d 
72 
20 OAc 23
e 28  OH 0.5 h 87 
c 
d 
60 
65 NO2 24
g 29  NO2 5 d 99 
29 h 30  NH2 1 h 99 
35
i
31  OCH3 2 d 50 
35
i
32  COOMe 5 d 39 
35
i
33  COOBn 4 d 43 
33
j
34  COOH 3 h 73 
Scheme 2. Reagents and conditions: (a) PPh3, EtOAc, NH3, CO2, rt, 88%; (b) H2, Raney-Ni, EtOAc, rt, 71%; (c) 4-R-C6H4–COCl, ZnCl2, CHCl3, reﬂux; (d) 4-R-C6H4–CONCO, CH3CN,
Ar, rt; (e) NaOMe, MeOH, rt; (f) AcCl, MeOH, rt; (g) KHSO4, MeOH, rt; (h) H2, Raney-Ni, MeOH, rt; (i) 4-R-C6H4–CONH2 converted to 4-R-C6H4–CONCO (by (COCl)2 in
ClC
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Ple native structure) was attributed to the bulky benzoyl moiety;
wever, these shifts were not in the direction of T to R allosteric
nversion. The conformational changes resulted in increased
ntacts between the inhibitor and the protein, providing a ratio-
lization for the Ki with a value of 4.6 lM. However, the ‘charac-
ristic’ hydrogen bond between amide nitrogen N1 and the
ckbone O of His377 was disrupted in RMGPb–15 complex.16 This
drogen bond was present in most RMGPb structures determined
complex with b-D-glucopyranosylamine analogues illustrated in
art 1.
.2. Compound 25
Introduction of amethyl (–CH3) group in the para-position of the
enyl ring resulted in an improved inhibitor with a Ki value of
lM compared to the lead compound 15. Structural studies of
GPb–25 complex showed that 25 bound at the catalytic site
d formed a total of 18 hydrogen bonds and 94 van der Waals
teractions (slightly reduced compared to 15, 20 and 103, respec-
ely) (Tables S2b and S2c and Fig. 2a and b). The aforementioned
aracteristic’ hydrogen bond between N1 and the main chain O
His377 was disrupted in accordance with the results observed
r Bzurea. The substituted phenyl ring pointed at a similar direction
that of15with a negligible incline (atoms shifted by0.4 to 0.7 Å)
wards Ala383 (Fig. 3a). The solvent structure was comparable in
H2CH2Cl at reﬂux temp., then reaction with 35 in Py, rt; (j) H2, Pd/C, MeOH, reﬂux.ease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (201th complex structures except for two water molecules, Wat161
and Wat235 O (numbering from RMGPb:15 complex structure)
at were displaced to avoid clashes with C15 of the methyl group.
few minor shifts were also recorded in the solvent lying in the
inity of the hydrophobic –CH3 group, that is Wat84 O shifts by
.7 Å, Wat215 O by 0.6 Å and Wat209 O by 0.5 Å (Wat93 O,
at251 O,Wat183 O numbering from RMGPb–15 complex, respec-
ely). The rearrangement of the solvent structure induces more
ofound changes in the 280s loop compared to those observed in
e Bzurea complex. In particular, the side chain of Asn282 became
s stable mainly due to the displacement ofWat235 O in the pres-
ce of the –CH3 group and changed conformation by rotation of its
hedrals (v1, v2) by (120, 33), respectively. As a result the side
ain of Asn284 is subjected to a minor shift in all atoms by 0.5 Å.
ilarmove (by0.5 Å in all atoms)was recorded for Phe285 since
e hydrogen bond formed between the backbone oxygen and
n282 ND2 was disrupted. Analogous changes were induced to
e side-chain atoms of Phe286 (atoms shifted by 0.5 to 0.7 Å and
rotated by 10). However, the most profound modiﬁcations,
ssibly interrelated to the new position of Asn282, were observed
Glu287 that adopted a different conformation (rotation of dihe-
al angles (v1, v2, v3) by (55, 18, 170), respectively) com-
red to RMGPb:15 complex structure. The peptide bond between
u287 and Gly288 also ﬂipped to restore stereochemistry.2), doi:10.1016/j.bmc.2011.12.059
Although binding of 25 seemed to provoke more profound changes
in the 280s loop than those of 15, and some perturbation in the
solvent structure, introduction of –CH3 appeared to be overall ener-
getically favourable since it outweighed those changes and resulted
280 in a better inhibitor than 15.
2.2.3. Compound 26
Replacement of the methyl group by another hydrophobic but
much bulkier substituent (–C6H5) in the para-position of the
phenyl ring was also investigated. The new compound exhibited
similar afﬁnity to 25 (Ki value of 3.4 lM) and bound at the catalytic
site with the phenyl ring been subjected to minor incline (atoms
shifted by 0.3 to 0.5 Å) compared to the corresponding one in
15 complex (Fig. 3b) towards Asn133 and Glu88 (unlike RMGPb:25
that moves slightly towards Ala383). The new aromatic ring intro-
290 duced was rotated by 38 to optimize its interactions with resi-
dues in the vicinity Asn282, Phe286, Arg292, and His341. The
(–C6H5) group occupied the subsite of the b-pocket at the catalytic
channel21 displacing three water molecules Wat84 O, Wat161 O
and Wat215 O upon binding to avoid clashes with C17 atom of
the second phenyl ring. These two waters were hydrogen bonded
to Wat235 O, also absent in the new complex structure that
was in turn interacting with Asn282 ND2. Disruption of this
water-mediated network destabilized the side chain of Asn282
ls
300 e
alteration of Asn282 side chain resulted in shifts in the range of
0.3 to 0.7 Å in both Asn284 and Phe285 side chain atoms and
more pronounced modiﬁcations in Glu287. The peptide bond
formed between Glu287 and Gly288 ﬂipped as in RMGPb:26 com-
plex and the side chain of the former also changed (rotation of
dihedral angle v3 by 61). Introduction of such a bulky substitu-
ent affects also the side chain of Arg292 the atoms of which are
slightly shifted away from the ligand (by 0.5 Å). Overall, 26 upon
binding maintains the number of hydrogen bond interactions
310formed compared with the methyl compound 25; however, the
increased number of van der Waals interactions (113) did not seem
to promote ligand binding (Fig. 2c, Tables S2b and S2c). The prefer-
ence though of the
b-pocket subsite for more hydrophobic and the space availability
for even bulkier substituents became evident.
2.2.4. Compound 27
To further investigate the type of interactions formed at the
catalytic site a chlorine atom (–Cl) was placed in position 4 of
the phenyl ring. Kinetic results indicated that afﬁnity of the new
320analogue was equivalent to that of the parent molecule (Ki value
of 4.4 lM). Analysis of the RMGPb:27 crystal structure showed that
it bound at the catalytic site in a similar fashion to the previous
analogues (Fig. 3c) making a total of 19 hydrogen bond and 91
-
Table 1
Kinetic data obtained with rabbit muscle GPb and crystallographic numbering of the compounds
O
HO
HO
OH
OH
O5
O2
O6
O3
O4 C5
C3
C2
C6C4
H
N
O
H
N
O
RC8
O8O7
N2
C7
N1
Compound R Ki (lM) Compound R Ki (lM)
15
C10
C11
C12
C13
C14
C9 4.6 ± 0.9016 30
NH2
C13
C12
C11
C10
C14
C9
N3
6.0 ± 0.60
25
CH3
C11
C12
C13
C14
C10
C9
C15
2.3 ± 0.03a 31
OCH3
3.2 ± 0.16
26
C17
C18
C19
C20
C16
C15
C11
C10
C13
C14
C9
C12 3.7 ± 0.06 32
COOCH3
4.0 ± 0.16
27
ClC11
C12
C13
C14
C9
C10
4.4 ± 0.09a 33
COOCH2Ph
150 ± 12a
28
OH
C13
C12
C11
C10
C9
C14
O12
6.3 ± 0.30 34
COOH
85 ± 6.5a
29
N
C11
C10
C13
C14
C9
O
O
O9
O10
C12 N3
3.3 ± 0.30
a Ki values for these compounds were calculated for comparison purposes by the Cheng–Prusoff equation: Ki = IC50/(1 + [S]/Km).
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(v1, v2) by (130, 35) similar to that in RMGPb:25. ThPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. ChemVan der Waals interactions (Fig. 2d, Tables S2b and S2c). The phe
nyl ring was. (2012), doi:10.1016/j.bmc.2011.12.059
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Plost coplanar with the one in 15, and only slight shift (by0.3 to
Å) of the carbon atoms towards Ala383 was observed compared
ure 1. Schematic representation of the 2Fo  Fc electron density maps contoured at 1
e, f for compounds 25, 26, 27, 28, 29, 30) and the new allosteric site (g, compound 2ease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (20115 when bound to RMGPb (Fig. 3c). Two water molecules are
splaced upon binding of 27 at the catalytic site; Wat161 O to
level of the reﬁned Bzurea analogues bound at the catalytic site of RMGPb (a, b, c,2), doi:10.1016/j.bmc.2011.12.059
330 5
o
l
n
d
-
O
7
,
340l
s
n
d
is
f
Figure 2. Stereo representation of the molecular interactions of compounds 15 (a), 25 (b) 26 (c), 27 (d), 28 (e), 29 (f), 30 (g) when bound at the catalytic site of RMGPb and
protein atoms in the vicinity. Water molecules are labeled as w. Emphasis is given in the new substituent introduced in the para-position of the phenyl ring of 15.
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25 January 2012avoid clashes with the chlorine atom and its neighboring Wat23
O that was not tightly bound at the catalytic site any more als
due to the conformational change of Asn282 side chain (dihedra
angles v1, v2 rotate by 120, 40, respectively) that resulted i
the disruption of the second hydrogen bond interaction it forme
with ND2 atom of the same residue. Additional alterations ob
served in the solvent structure involved shifts of Wat215
(Wat257 O numbering from GPb:25 complex), Wat84 O (Wat8Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. ChemO), Wat236 O (Wat186 O), Wat148 O (Wat270 O) by 0.8, 0.7
0.3, 0.9 Å, respectively. Overall, residues of the 280s loop follow
the same rearrangement observed for in the RMGPb:15 crysta
structure except for Asn282. Upon ligand binding, residue
Asn284, Phe285, Phe286 are subjected to minor disturbance (i
the range of 0.3 to 0.7 Å). More extensive changes are recorde
for Glu287 the peptide bond of which with Gly288 ﬂipped in th
complex structure as well. Despite the increased perturbation o. (2012), doi:10.1016/j.bmc.2011.12.059
th
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Ple 280s loop residues it appeared that the addition of chlorine
om and the amendments of the solvent structure at the catalytic
bsite outweighed the energy loss and resulted in an inhibitor as
tent as the lead compound.
.5. Compound 28
Replacement of the chlorine atom by –OH in the para-position
the phenyl ring appeared to be less favourable as indicated by
Fig. 2 (conease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (201e kinetic evaluation (Ki increased to a value of 6.3 lM). Com-
und 28 bound at the catalytic site of RMGPbwith the phenyl ring
oms lying in approximately the same position as in Bzurea
toms shift by 0.3 Å) (Fig. 3d). It induced similar conformational
anges in the 280s loop residues to the ones observed previously
Bzurea complex, but less extended than those in the complex
uctures of compounds 25, 26 and 27. Most of the residues lining
e 280s loop including Asn282 were subjected only to subtle
ed)2), doi:10.1016/j.bmc.2011.12.059
changes (atoms shifted by 0.3 to 0.5 Å in Asn282, Asn284,
Phe285, Phe286) and the most profound difference is that observed
in the ﬂipping of the peptide bond between Glu287 and Gly288 in
accordance with the aforementioned 4-subsituted Bzurea ana-
logues. In general, the ligand’s contacts with protein and water
residues in the vicinity of the catalytic site were almost maintained
compared to RMGPb:15 structure (22 hydrogen bonds, 104 van der
Walls interactions) (Fig. 2e). Focusing on the –OH group (atom O12
of 28) the complex structure showed that it was implicated in po-
370 tential water-mediated interactions with the side chain atoms of
residues Glu88, Arg292, Glu385 and the backbone oxygen atoms
of Tyr280, Asn282 and Ala383 through water molecules Wat86
O, Wat166 O, Wat224 O, Wat244 O andWat333 O. Little rearrange-
ment was also observed in the solvent structure in the environ-
ment ranging from 0.3 to 0.8 Å involving mainly water
molecules Wat84 O, Wat161 O, Wat215 O, Wat235 O). Apparently,
the results indicated by RMGPb:28 complex structure indicated
that –OH was not advantageous, although it induced less modiﬁca-
tions upon binding compared to the rest of the analogues studied.
380 2.2.6. Compound 29
Substitution of –OH group by a –NO2 group resulted in a slightly
more potent inhibitor with a Ki of 3.3 lM. Structural results derived
from RMGPb:29 complex showed that binding of the new analogue
caused an incline of the phenyl ring by 10 compared to Bzurea
and shifts of the corresponding carbon atoms in the range of 0.4
and 0.8 Å (Fig. 3e). Binding of 29 was stabilized by an extended
network of hydrogen bond interactions with the catalytic site resi-
dues, mainly through water molecules. The total number of hydro-
gen bonds was increased to 23 as compared to 20 in the case of
390 Bzurea and van der Waals interactions were maintained to 103
(Fig. 2f, Tables S2b and S2c). Two water molecules, Wat161 O and
Wat235 O (numbering from RMGPb:15) were displaced upon li-
gand binding to avoid clashes with O10 of the –NO2 group. The li-
gand oxygen O9 is hydrogen bonded to Arg292 NE, NH2 and
Glu385 OE2 (through Wat86 O) to Asn282 ND2 and Glu287 N, O
(throughwatersWat315,Wat316), to Tyr280 O, Asn282 O (through
waters Wat316 andWat224) and Glu88 OE1 and Arg292 NH1, NH2
).
y
400 d
s
,
t
f
the solvent structure appeared in the rest of the catalytic channel
with shifts in the range of 0.4 to 0.9 Å. The side chain of
Asn282 adopts an alternate conformation (torsion angles v1, v2
rotate by131 and36, respectively) similar to the one observed
in the rest of the Bzurea analogues studied except –OH. Further
410changes recorded in the 280s loop residues involve the side chain
atoms of Asn284 (shifted by 0.3 to 0.5 Å), Phe285 (rotation of
dihedral v2 by 15 and Ca shifted by 0.5 Å), Phe286 (all atoms
shifted by 0.5 to 0.8 Å) and Glu287 (rotation of dihedrals, v1,
v2, v3 by 18, 20, 131, respectively and atoms shifted by 0.7
to 1.6 Å). The backbone atoms of Glu287 occupied a new position
at 0.3 to 0.5 Å away from the one in RMGPb:15 promoting the
change of the peptide bond with Gly288 by 180. Despite the
extended changes that binding of 29 induces at the catalytic site
of the enzyme mainly in the 280s loop residues Asn282 and
420Glu287 along with the rearrangement of the solvent structure to
accommodate the –NO2 group, the results indicated that binding
of 29 is favourable stabilizing the 280s loop in the closed conforma-
tion a little better compared to the lead compound Bzurea.
2.2.7. Compound 30
Further modiﬁcation involved introduction of a –NH2 group in
the para-position of the phenyl ring that resulted in a less potent
inhibitor comparedwith 15with a Ki value of 6.0 lM. The structural
data from the RMGPb:30 complex showed that the phenyl ring in-
clined slightly (12) when the new substituent was introduced
430and the carbon atom C12 showed a minor shift (less than 0.5 Å)
(Fig. 3f). The network of interactions formed by 30 upon binding
was very similar to that of Bzurea (21 hydrogen bonds, 98 van der
Waals contacts) (Fig. 2g). N3 Atom of the –NH2 group did not form
any direct hydrogen bonds with residues lining the catalytic site,
however, it was involved in water mediated contacts with the
280s and 380s loop residues as well as Arg292, through water mol-
ecules Wat86, Wat166 and Wat224 (Fig. 2g). The 280s loop adopts
the same orientation as in the RMGPb:15 complex structure with
minor conformational changes. The position of Asn284 side chain
440atoms changed by 0.3 to 0.4 Å and similar shifts were recorded
for the main chain atoms of Phe285 while its dihedral angle v2 ro-
3
d
-
n
l-
d
),
Fig. 2 (continued)
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25 January 2012(through waters Wat316, Wat224 and Wat218) (Fig. 2f, Table S2b
In addition, the solvent network got slightly distorted particularl
at the b-pocket where the positions of water molecules change
to optimize the interactions upon binding of 29. In speciﬁc, water
Wat224 O, Wat86 O, Wat245 O, Wat218 O shifted by 1.0, 0.6
0.4,1.1 Å, respectively, inducing displacement of Wat231 O tha
is missing in the new complex structure. Minor rearrangement oPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chemtated by 18. The backbone atoms of Phe286 also shifted by 0.
to 0.5 Å and the most signiﬁcant change was in the peptide bon
between Glu287 and Gly288 that ﬂipped also in this complex struc
ture compared to RMGPb:15. Only minor changes were observed i
the water structure at the catalytic site upon binding of 30 to faci
itate the interactions formed by N3 of the amino group introduce
with the environment. These involve shifts ofWat250 O (by1.2Å. (2012), doi:10.1016/j.bmc.2011.12.059
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Plat244 O (by 0.5Å) and waters Wat86 O, Wat251 O, Wat42 O,
at224 O and Wat245 by 0.4 Å. Although the perturbation that
mpound 30 induced is rather limited analogous to the one of
the structural results suggest that possibly the cost of the confor-
ational energy to transfer the compound from the solvent to the
talytic site of the RMGPb could not be compensated by the in-
ased hydrogen bond interactions formed.
ure 3. Stereo diagrams of the structures of RMGPb in complex with Bzurea (15) (sh
own in light grey; yellow in web).ease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (201. Computational studies
Recently, computational studies on small molecule inhibitors of
cogen phosphorylase were surveyed.22 Also, the performance of
fferent docking programs were evaluated on glycogen phosphor-
se.23 This study showed that the GLIDE docking program was the
st performing one with the lowest RMSD to the crystal structure
in dark; cyan in web) and compounds 25 (a) 26 (b), 27 (c), 28 (d), 29 (e), 30 (f)2), doi:10.1016/j.bmc.2011.12.059
470
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25 January 2012orientations and that scoring function in the GLIDE program corre-
late well with experimental Ki values.24
In the present study, to further test the predictive power and
reliability of available computational methods, nine inhibitors
were docked to two glycogen phosphorylase structures derived
from complexes of RMGPb with inhibitors 15 (protein structure
called Bzurea) and N-(2-naphthoyl)-N0-(b-D-glucopyranosyl)urea
(Fig. 4) (protein structure called 2-Nap-urea) using the GLIDE pro-
gram. The docked inhibitors conformations with the lowest Glide-
Score were chosen for further evaluation of binding afﬁnity using
LiaScore calculated with LIAISON program. The resulting scores are
compared with experimental Ki, computed lnKi and DG values in
Fig. 3 (c
Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. ChemTable 2. The comparison of the geometry of docked structure for
inhibitor 15-Bzurea and N-(2-naphthoyl)-N0-(b-D-glucopyrano-
syl)urea-2-Nap-urea complexes can be seen in Figures 5 and 6,
respectively. Figure 7 shows the best docked poses for all inhibitors
in the active site of 2-Nap-urea glycogen phosphorylase. Correla-
tion of experimental lnKi values with predicted LiaScore is given
480in Figure 8.
To evaluate the accuracy of Glide docking, the best docked poses
of 15 and 2-Nap-urea were compared with their X-ray conforma-
tions in complex with the glycogen phosphorylase and pyridoxal-
50-phosphate. The best poses for the docked structures were chosen
on the bases of the GlideScore. First, we noticed that the docked
ontinued)
. (2012), doi:10.1016/j.bmc.2011.12.059
poses were correctly predicted (Figs. 5 and 6). It appears that a bet-
ter accuracy was observed for the case of the 2-Nap-urea complex.
This is also documented by the calculated RMDS of 2.117 Å for Bzu-
rea and 0.726 Å for 2-Nap-urea complex, respectively. Second, a
490 thorough analysis of the docked structure in Bzurea indicates that
glucose location is correctly predicted and the main deviation
comes from the urea part. The glucose moiety of 15makes H-bond
interactions with protein side chains, namely Glu672 and Asn484,
similarly as in the crystal structure, however due to different orien-
tation of the C6 hydroxyl group, does not interact with His377. The
urea conformation presented in the docked pose is s-trans whereas
in the crystal structure is s-cis. This conformational change is
re
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Figure 4. Structure of inhibitor N-(2-naphthoyl)-N0-(b-D-glucopyranosyl)urea (Ki
0.35 lM).17
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Plsponsible for slightly different binding of the phenyl group. We
sume that a removal of water molecules from protein structure
ight be one of the reasons for the conformational change. In fact,
e interactions of thesewatermoleculeswith the urea carbonyls in
stal structure are not assumed in docking procedure. We note
at the phenyl moiety is partially exposed to solvent and the phe-
l ring interactions might not be well described in the scoring
nction. It is noteworthy that docking of 15 into the binding site
2-Nap-urea led to the docked pose with the s-cis conformation
urea part as it is in crystal structure of Bzurea (not shown). Figure
hows that the binding mode of all studied inhibitors is similar to
at of 15. Also the relevant glucose–protein interactions observed
15 complex are preserved. Measured RMSD values (Å) for the
st docked poses of the inhibitors are shown in the Table 2. RMSD
smeasured only between heavy atoms in the common inhibitors
rts, namely N-benzoyl-N0-b-D-glucopyranosyl urea part. Values
r RMSD are in interval 1.009–6.858 Å for Bzurea and 0.680–
82 Å for 2-Nap-urea structures, respectively. These values indi-
te that structures docked into the 2-Nap-urea structure are more
ecise as documented by smaller RMSD values. The largest ob-
rved RMSD of 6.858 Å is for the 29 docked pose in the Bzurea
ucture. On the other hand, 29 has the lowest measured RMSD
lue 0.680 Å in the 2-Nap-urea structure. The smaller RMSD of
09 Å in the Bzurea is found for 30. The largest difference from
e 2-Nap-urea X-ray structure was observed for 15. This might re-
ct an inﬂuence of the larger binding pocket, which has responsi-
ity for a different binding mode.
It is well know that the docking accuracy of ligand depends on
e protein structure. When docking 15 into the Bzurea and
2-
ob
sid
gr
ﬂe
ac
le 2
mparison of the experimental data with the calculated GlideScores, LiaScores and RMSD to t
p-urea structures of glycogen phosphorylase
Name Experiment
Ki (lM) lnKia (lM) DGa (kcal/mol) Gscore
25 2.3 0.8329 7.74 6.99
31 3.2 1.1632 7.55 6.70
29 3.3 1.1939 7.52 6.78
26 3.7 1.3083 7.46 7.80
32 4.0 1.3863 7.41 7.35
27 4.4 1.4816 7.35 7.97
15 4.6 1.5261 7.33 7.38
30 6.0 1.7918 7.17 7.48
28 6.3 1.8405 7.14 8.26
perimental Ki values are taken from Table 1.
Calculated from Ki values.
ease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (201ure 6. The docked structure of the inhibitor N-(2-naphthoyl)-N0-(b-D-glucopyr-
osyl)urea into binding site of the glycogen phosphorylase 2-Nap-urea structure,
stal structure shown in sticks, docked structure in ball and stick representation.
e calculated RMSD is 0.726 Å.
ure 5. The docked structure of inhibitor 15 into binding site of the glycogen
osphorylase Bzurea structure, crystal structure shown in sticks, docked structure
ball and stick representation. The calculated RMSD is 2.117 Å.Nap-urea structures of the glycogen phosphorylase we have also
served small differences, as discussed above. This led us to con-
er reﬁnement and rescoring of docking poses using LIAISON pro-
530am, in which the ﬂexibility of protein, or more precisely the
xibility of protein side chains, is to some extent taken into
count. Therefore, all saved docking poses from Glide docking
he X-ray ligand common part for the best docked into binding site of Bzurea and 2-
Bzurea 2-Nap-urea
LiaScore RMSD Gscore LiaScore RMSD
12.98 1.626 7.07 13.12 2.009
15.09 1.997 8.60 12.49 0.907
14.25 6.858 8.70 15.61 0.680
14.81 1.732 8.05 14.59 1.785
13.60 3.761 7.71 14.26 2.260
13.11 1.753 7.52 13.54 1.987
11.14 2.117 7.30 12.99 2.382
11.32 1.009 8.56 11.97 0.924
12.55 2.219 8.28 10.30 1.334
2), doi:10.1016/j.bmc.2011.12.059
540
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prediction strength we observed with ﬁt without both outliers 25
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the predicted Ki value from the regression equation is 5.0 lM. The
t
f
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e
f
t
t,
s for d
e
kwere used as starting position and were fully optimized usin
Liaison and resulting structures were ranked using LiaScore. Th
results are listed in Table 2. Then we turned our attention to th
comparison of the predicted activities with the experimental dat
As can be seen from data in Table 2, the most active 25 was no
predicted as the strongest inhibitor of the set with both score func
tions and for both protein structures. GlideScore for any of the pro
tein structure does not correlate well with the observed activitie
(R2 values are around 0.1 with opposite slope and linear correlatio
was not observed). The Liaison results appeared as the best an
LiaScore correlate with experimental data reasonably well. Th
computed R2 values for both receptors are given in the Table 3
We have performed three different linear ﬁts for both receptor
The ﬁrst one included all computed Liascore’s. Values of 25were ex
cluded in the second and values for 25 and 31 in the third linear ﬁ
respectively. The calculated R2 values are in the interval from
0.3137 to 0.6455 and from 0.3067 to 0.9501 for Bzurea and 2
Nap-urea protein structure, respectively. Calculated R2 values show
that for all data and 25 excluded ﬁts the results are comparable. Fo
2-Nap-urea structure ﬁt, an improvement was found after th
exclusion of both outliers 25 and 31. However, for Bzurea structur
ﬁt the worse R2 value was observed (Table 3). However, the bes
Figure 8. Plot of correlation of experimental lnKi values with predicted LiaScore
from the ﬁt.
Figure 7. Overlays of the best docked poses of inhibitors into binding site of th
glycogen phosphorylase 2-Nap-urea structure. Docked structures are shown in stic
representation.Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. ChemTable 3
Comparison of the R-squared (R2) for the LiaScore versus lnKi ﬁt for both recepto
with different data sets
Bzurea 2-Nap-urea
All data ﬁt 0.31373 0.30675
data w/o 25 ﬁt 0.64555 0.57601
data w/o 25 and 31 ﬁt 0.55054 0.95005and 31, which correctly predict afﬁnity order of the docked struc
tures except for both outliers, of course. For the third ﬁt, in whic
the inhibitors with the largest difference (25 and 31) wher
excluded, the calculated R2 value is 0.9501. Different results o
docking using Bzurea and 2-Nap-urea protein structures show a
important role of the used protein structure on the prediction o
inhibitors potency, though these data were obtained only with nin
ligands. The protein structure 2-Nap-urea was found to be a fa
representative of protein structure for virtual screening. We as
sume that larger binding site of 2-Nap-urea compared to that i
Bzurea is responsible for this fact. On all data we applied linea
regression, with general equation LiaScore = A + B ⁄ lnKi, where
and B are regression parameters. As expected, the best correlatio
was found for LiaScore with 2-Nap-urea protein structure. Th
results are plotted on Figure 8 together with 95% conﬁdence limi
The resulting regression parameters are24.15 and 7.20 with erro
1.12 and 0.74, respectively, and the value of R2 is 0.9501. The corre
lation between calculated LiaScore and experimentally measured K
values is good. On Figure 8 can be seen that except value for tw
outliers, 25 and 31, all predicted values are in the range of 95
conﬁdence limits. The largest deviation from the correlation, as ex
pected, was observed for 25. The experimental value of Ki for the 2
is 2.3 lM whereas predicted Ki applying correlation equation from
the Liaison is 4.6 lM. The second largest difference has been ob
served for the 31. The experimental Ki value is 3.2 lM in this cassecond correlation where only 25 was excluded from the ﬁ
(R2 = 0.5760), has A and B values 20.53 and 5.00 with an error o
2.59 and 1.75 respectively. The predicted Ki values with this corre
lation for 25 and 31 are 4.4 and 5.0 lM, respectively. The differenc
between these two correlations is negligible. The comparison o
predicted and experimental Ki values for 25 and 31 shows tha
predicted Ki value for 25 and 31 are underestimated. At presenthe docked poses in 2-Nap-urea structure. The compounds 25 and 31 were exclude. (2012), doi:10.1016/j.bmc.2011.12.059
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Plhave no rational for such a large error. However, we cannot ex-
de a possibility of a different binding mode for these inhibitors,
used by the so called 280s loop (280–289 amino acid residues)
xibility. Also it is known that lipophilic and stacking interactions
the methylphenyl group are usually poorly described by scoring
nctions. We also note that our case is not unique, e. g. swainso-
ne that is most active inhibitor of mannosidase II was predicted
be one of the weakest inhibitors with several scoring functions,
ough its binding mode was predicted correctly. This shows that
ere is a room for improvement of scoring functions.
Conclusions
N-(4-Substituted-benzoyl)-N0-b-D-glucopyranosyl urea deriva-
eswere prepared by ZnCl2 catalysed acylation of O-peracetylated
D-glucopyranosyl urea or reacting O-peracetylated b-D-glucopyr-
osylamine with acyl-isocyanates and subsequent deprotection.
me compounds were prepared, to avoid protecting group manip-
ations, in reactions of b-D-glucopyranosylammonium carbamate
th acyl-isocyanates. Substituents of neutral polar and apolar as
ll as acidic and basic character were introduced in the 4-position
the phenyl ring with the aim to exploit the available space at the
bsite of the b-pocket of the active site of glycogen phosphorylase
king into account the solvent structure. Most of the new com-
unds were low micromolar inhibitors of rabbit muscle glycogen
osphorylase b, however, no signiﬁcant improvement of the
hibitory efﬁciency as compared to that of N-benzoyl-N0-b-D-glu-
pyranosyl urea could be observed. These ﬁndings might indicate
e lack of a speciﬁc and crucial interaction from this position with-
the catalytic site.
Crystallographic analyses of the 3D structures of the new com-
unds with RMGPb showed clearly that all analogues induced a
ore extended shift of the backbone atoms of the 280s loop com-
red to RMGPb:15. This shift was facilitated by the ﬂipping of the
ptide bond formed between Glu287 and Gly288 to create more
ace at the catalytic site of the enzyme. The most profound differ-
ces were observed in the side chain of Asn282 that adopted a
odiﬁed conformation upon ligand binding in all complexes
cept for –OH and –NH2 groups. Overall, the structural results
re in accordance with those obtained by the kinetic evaluation
the compounds. The best inhibitor identiﬁed was compound
(4-CH3 group) that formed increased van der Waals interactions
th the residues lining the catalytic site. The second best inhibi-
r, out of those studied by X-ray crystallography, was compound
(4-NO2 group) that stabilized the closed conformation of the
0s loop and as well as residues at the far end of the b-pocket
ch Arg292 through an extended network of water-mediated
teractions. Compound 29 formed the largest number of hydrogen
nds at the catalytic site compared to the rest of the compounds.
e results obtained suggest the key role of the solvent structure in
ucture-based ligand design. This could be exploited for the
sign of more potent inhibitors of enzyme activity coupling the
owledge derived from each complex structure with geometric
orithms.25
The compounds 15, 25–32 were docked into the Bzurea and
Nap-urea crystal structure of the glycogen phosphorylase,
spectively. The binding afﬁnity of the highest ranked docked
ses was predicted by the LIAISON program (LiaScore) and corre-
ed with experimentally measured Ki values of the studied inhib-
rs. The quality of the correlation was assessed using the R-
uared (R2) coefﬁcient. The value of the R2 ranges from 0.1080
to 0.9180. Generally, a better correlation was found for the
uctures docked into the 2-Nap-urea structure. The best correla-
n was achieved for the correlation where two outliners, 25 and
, were excluded from the linear ﬁt, with linear correlation coef-ease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (201ients A and B (A + B ⁄ x) having values of 23.89 and 7.12. Inter-
tingly, the best measured inhibitor appears as an outliner. This
uation might be caused by the different binding mode predicted
the docking and absence of the water molecules present in the
tive site as have been shown in presented crystal structure. De-
ite all this, presented linear ﬁt can be used to predict the binding
nity for compounds having the same scaffold structure by the
ISON program.
Experimental
. General synthetic methods
Melting points were measured in open capillary tubes or on a
ﬂer hot-stage and are uncorrected. Optical rotations were deter-
ined with a Perkin-Elmer 241 polarimeter at room temperature.
R spectra were recorded with Bruker WP 200 SY (200/50 MHz
r 1H/13C), Bruker AM 360 (360/90 MHz for 1H/13C) or Bruker
400 (400/100 MHz for 1H/13C) spectrometers. Chemical shifts
e referenced to Me4Si (1H), or to the residual solvent signals
C). TLC was performed on DC-Alurolle Kieselgel 60 F254 (Merck)
luent EtOAc–hexane 1:2, unless stated otherwise), and the spots
re visualized under UV light and by gentle heating. For column
romatography Kieselgel 60 (Merck, particle size 0.063–
00 mm) was used. Organic solutions were dried over anhydrous
gSO4 and concentrated under diminished pressure at 40–50 C
ath temperature). Acetonitrile was distilled from P4O10 and
red over molecular sieves (3 Å). Dry methanol was distilled
m magnesium methylate. Other solvents of commercial analyt-
l grade quality were used without further puriﬁcation.
. General methods for the preparation of N-acyl-N0-(2,3,4,6-
tra-O-acetyl-b-D-glucopyranosyl)ureas
.1. Method A
To a solution of an acyl chloride (7.7 mmol) in 20 ml of dry chlo-
form anhydrous zinc chloride (80 mg, 0.59 mmol) and 2,3,4,6-tet-
-O-acetyl-b-D-glucopyranosyl urea (16, 1 g, 2.56 mmol) were
ded with stirring. The reaction mixture was reﬂuxed until TLC
owed the complete transformation of 16. Then the reaction mix-
re was poured into ice-water and was extracted with chloroform
). The organic phases were collected and washed with satd aq
2CO3 solution andwater. After drying the solventwas evaporated
d the residue was puriﬁed by column chromatography (eluent:
OAc–hexane = 1:2).
.2. Method B
To a suspension of NaOCN (1.21 g, 18.7 mmol) in dry acetoni-
le an acyl chloride (14.4 mmol) in acetonitrile (30 ml) and SnCl4
4 ll, 0.72 mmol) were added under argon with stirring. The mix-
re was stirred under reﬂux for 8 h and after cooling to rt 2,3,4,6-
tra-O-acetyl-b-D-glucopyranosyl amine (18, 1 g, 2.88 mmol) was
ded under argon. After stirring for 30 min some drops of water
re added and the mixture was ﬁltered. The solvent was evapo-
ted and the residue puriﬁed by column chromatography (eluent:
OAc–hexane = 1:1).
. General methods for the preparation of N-acyl-N0-
D-glucopyranosyl)ureas
.1. Method C
A solution of an N-acyl-N0-(2,3,4,6-tetra-O-acetyl-b-D-glucopyr-
osyl)urea in dry methanol was treated with a catalytic amount2), doi:10.1016/j.bmc.2011.12.059
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25 January 2012of a methanolic solution of NaOMe at rt. After TLC had show
disappearance of the starting material the reaction mixture wa
neutralized with a cation exchange resin (Amberlyst 15, H+ form
After ﬁltration the solvent was removed and the residue was pur
ﬁed by crystallisation.
4.3.2. Method D
A solution of an N-acyl-N0-(2,3,4,6-tetra-O-acetyl-b-D-glucopyr
anosyl)urea in dry methanol was treated with a catalytic amoun
of acetyl chloride at rt. After TLC had shown disappearance o
the starting material the reaction mixture was neutralized wit
solid NaHCO3. After ﬁltration the solvent was removed and the res
idue was puriﬁed by column chromatography (eluent: CHCl3
MeOH = 9:1).
4.3.3. Method E
Oxalylchloride (1.1 equiv) was added to a suspension of a car
boxamide (0.15 mmol) in anhydrous 1,2-dichloroethane (2 mL
and the mixture was heated at reﬂux temp. for 1 d. The volatile
were distilled off under diminished pressure and toluen
(2  5 mL) was evaporated from the residue to remove the rest
s
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e.of oxalylchloride. The acyl-isocyanate obtained in this way wa
mixed with a solution of b-D-glucopyranosylammonium-carba
mate20 (1 equiv) in anhydrous pyridine (100 mg/14 mL) and th
mixture was stirred until TLC (CHCl3–MeOH = 7:1) showed n
more change (transformations were incomplete). Pyridine was dis
tilled off under diminished pressure and evaporation of toluen
(2  30 mL) removed traces of pyridine. The crude was puriﬁe
by column chromatography (CHCl3–MeOH = 7:1).
Particular syntheses and compound characterization data ar
presented in the Supplementary data.
4.4. Enzyme preparation
RMGPbwas isolated from rabbit skeletal muscle and puriﬁed a
described previously.26 Kinetic studies were performed in th
direction of glycogen synthesis in the presence of various concen
trations of inhibitors as indicated in Table 1. Enzyme activity wa
measured at pH 6.8 by the release of inorganic phosphate as de
scribed previously by Oikonomakos et al.27 (compounds 27, 2
and 30) and Saheki et al.28 (compounds 21, 23 and 25).
4.5. Crystal complex formation and X-ray crystallographic dat
collection and processing
Native T-state GPb crystals were grown in the tetragonal lattic
space group P4321229 and prior to data collection were soaked in
buffered solution (10 mM Bes, pH 6.7) with 6.2 mM of 21 (for 2 h
0.76 mM of 23 (in 20% DMSO for 84 h), 1 mM of 25 (in 2% DMSO fo
10 h), 10 mM of 29 (for 1 h). Co-crystals of RMGPb complexed wit
27 and 30 were obtained in a medium consisting of 20 mg/ml en
zyme, 1 mM spermine, 3 mM DTT, 10 mM BES, 0.1 mM EDTA
0.02% sodium azide, pH 6.7 (16 C) with either 5 mM of 27 o
7 mM of 30. Diffraction data for all complexes were collected from
n
1
)
e
n
d
e
-
820d
-single crystals at room temperature, using synchrotron radiatio
source at EMBL-Hamburg outstation, Germany, beamlines X3
(k = 0.8123 Å), X11 (k = 0.813 or 0.8468 Å), BW7A (k = 0.9076 Å
and BW7B (k = 0.8441 Å), and SRS-Daresbury Laboratory, beamlin
PX9.6 (k = 0.92 Å). Integration of the reﬂections and data reductio
was performed using the programs DENZO and SCALEPACK from
HKL-package.30
4.6. Crystal structure determination
The structure of RMGPb in complex with 15, previously deter-
mined at 1.8 Å resolution16 with XPLOR (pdb code 1K06) was
l
Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chemreﬁned using REFMAC.31 The results showed that residues linin
the 280s loop exhibited differences in their side chain orientation
with the most profound ones localized in residues Asp283 (u, w
v1, v2 change by 14, 51, 166, 20, respectively) and Glu287 (u
w, v3) change by 22, 35, 156, respectively). The new mode
deposited with the protein data bank (pdb code 2QNB), as replace
ment of 1K06, was used as a starting model for the structure deter
mination of all six complexes. Crystallographic reﬁnement wa
carried out using a standard protocol as implemented by REF
MAC.31 2Fo  Fc and Fo  Fc electron density maps calculated wer
visualized using the program for molecular graphics ‘O’.32 Ligan
models were ﬁtted to the electron density maps after adjustmen
of their torsion angles. Alternate cycles of manual rebuilding wit
‘O’ and reﬁnement with REFMAC improved the quality of the mod
els. The data collection and reﬁnement statistics along with th
model quality are summarized in Supplementary data Table S2a
The stereochemistry of the protein residues was validated b
PROCHECK.33 The analyses of the complex structures comprise
mapping of the hydrogen bond and van der Waals interactions o
the analogues with the residues lining the catalytic site usin
CONTACT33 applying a distance cut off 3.3 and 4.0 Å between th
electronegative atoms, respectively. The program calculates th
angle O  H  N (where the hydrogen position is unambiguous
and the angle source  oxygen-bonded carbon atom. Suitable va
ues are 120 and 90. The network of interactions is described i
Tables S2b and S2c. Structural comparisons were performed wit
the program ‘O’32 by superposition of the atomic coordinates o
the new complexes with those of the RMGPb:Bzurea structur
The root mean square deviation in Ca positions were determine
for residues (24–249), (261–281), (289–313), (326–549) an
(558–830) using LSQKAB.33
All ﬁgures were prepared with the programs MolScript34 an
BobScript35 and rendered with Raster3D.36
The coordinates of the new structures have been deposited wit
the RCSB Protein Data Bank (http://www.rcsb.org/pdb) with code
2QNB-15, 2QLM-25, 2QLN-26, 2QN3-27, 2QN7-28, 2QN8-29 an
2QN9-30.
4.7. Preparation of protein and ligand structures for docking
The initial structures of the glycogen phosphorylase in a com
plex with pyridoxal-50-phosphate and N-benzoyl-N0-b-D-glucopyr
anosyl urea 15 and N-(2-naphthoyl)-N0-b-D-glucopyranosyl ure
(2-Nap-urea) were obtained from the PDB database under th
codes Bzurea and 2-Nap-urea, respectively, and prepared usin
Schrodinger’s Maestro and Protein Preparation Wizard37 as fo
lows. Water molecules were removed, hydrogen atoms were adde
and protonation states were assigned based on a residue pKa’s a
their normal pH (7.0). Atom types and partial charges were as
signed according to the OPLS_2001 force ﬁeld, also known a
OPLS-AA.38
Docking grids were prepared for each of the prepared protei
structures, Bzurea and 2-Nap-urea, using the same procedur
The centers of the cubic grid boxes were placed on the centroi
of the bound ligands and the box sizes were set to 14 Å in all thre
dimensions.
Nine inhibitors with available experimental Ki data were se
lected for this study. The structures of all inhibitors were obtaine
through the energy minimization using Jaguar v7.0 program in
cluded in the Schrodinger software37 at the DFT B3LYP39,40 leve
with the 6-31+G⁄ basis set41–46 prior to the docking. The calculated
ESP charges were used as input partial charges for ligand atoms in
the docking calculations.
Docking was carried out using the Glide v4.5 package of Schro-
dinger suite 2007.37 Recent review of docking programs showed47
that Glide belongs amongst the most accurate docking programs.
. (2012), doi:10.1016/j.bmc.2011.12.059
We have used ﬂexible ligand docking with the standard precision
830 (SP) algorithm.48 The parameters for van der Waals radii were
scaled by 0.80 for ligand atoms with partial atomic charge less then
0.15. Ligand poses were clustered with RMSDs less than 0.5 Å and
within maximum atomic displacement less than 1.3 Å. After the
docking procedure 20 poses of each docked ligand with the best
GlideScore49 were saved and used for the analysis.
Binding afﬁnities were recalculated for all saved docking poses
employing the program Liaison included in the Schrodinger soft-
ware.37 The structures of the complexes using the OPLS2005 force
ﬁeld50 were optimized and the LiaScore’s (‘GlideScore in Liaison’)
840 analyzed for the relaxed complexes. Enzyme ligand complexes
were optimized with a restrained mobility of receptor residues at
distance larger than 12 Å and with frozen residues at distance lar-
ger than 16 Å from ligand, respectively. The same DFT calculated
partial atomic charges were used for the ligand as for the docking.
Implicit solvent continuum model have been used in computation
to model solvent effects. The calculated LiaScore for the best
docked pose were correlated with the experimentally measured
lnKi values.
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